SCHEMBL29965768

SCHEMBL29965768

Cn1cc(C(=O)O)c2ccccc21

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.72
NR4A2 P43354 1/20 0.67
LMNA P02545 2/20 0.66
KMT2A Q03164 3/20 0.65
ALDH1A1 P00352 2/20 0.65
MAPT P10636 2/20 0.65
MITF O75030 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
HTT P42858 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.58
TSHR P16473 1/20 0.54
ALOX12 P18054 1/20 0.54
MEN1 O00255 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535878 1.00 POLB (0.72) POLBNR4A2LMNAKMT2AALDH1A1
Hydrochloric Acid SCHEMBL2434452 0.98 POLB (0.70) POLBNR4A2LMNAKMT2AALDH1A1
Tert-Butylbenzene SCHEMBL27728888 0.89 POLB (0.59) POLBNR4A2LMNAKMT2AALDH1A1
SCHEMBL5468019 0.87 POLB (0.57) POLBNR4A2LMNAKMT2AALDH1A1
SCHEMBL30421484 0.87 POLB (0.61) POLBNR4A2LMNAKMT2AALDH1A1
SCHEMBL398161 0.87 POLB (0.61) POLBNR4A2LMNAKMT2AALDH1A1
SCHEMBL1558956 0.85 POLB (0.68) POLBNR4A2LMNAKMT2AALDH1A1
SCHEMBL1887873 0.85 NR4A2 (0.67) POLBNR4A2LMNAKMT2AALDH1A1
SCHEMBL29848366 0.85 NR4A2 (0.67) POLBNR4A2LMNAKMT2AALDH1A1
SCHEMBL21437406 0.84 POLB (1.00) POLBNR4A2LMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN claimed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP claimed
US-20250236590-A1 A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES DEB INDUBHUSAN 2025-07-24 US disclosed
US-20250090498-A1 TREATMENT OF PRIMARY CTLA-4 CHECKPOINT RELATED IMMUNODEFICIENCIES ADIENNE PHARMA & BIOTECH SA (CH) 2025-03-20 US disclosed
WO-2024261641-A1 TREATMENT OF PRIMARY CTLA-4 CHECKPOINT RELATED IMMUNODEFICIENCIES WITH 1H-INDOLE-3-CARBOXALDEHYDE OR 1-METHYLINDOLE-3-CARBOXYLIC ACID ADIENNE PHARMA & BIOTECH SA (CH) 2024-12-26 WO disclosed
EP-4419503-A1 A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) 2024-08-28 EP disclosed
CN-118255685-A Tricyclic compound, pharmaceutical composition and application thereof 珂阑(上海)医药科技有限公司 2024-06-28 CN disclosed
CN-110637015-B Fanisole X receptor agonist and application thereof 奥加诺沃公司 2024-04-02 CN disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP disclosed
WO-2023067628-A1 A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2023-04-27 WO disclosed
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2022-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof TPMT, TET1, TET2 POLB 371/4885NR4A2 3571/4885LMNA 3290/4885
US-20250090498-A1 TREATMENT OF PRIMARY CTLA-4 CHECKPOINT RELATED IMMUNODEFICIENCIES CD274, PDCD1, ICOS POLB 1018/4885NR4A2 2836/4885LMNA 4630/4885
US-20250236590-A1 A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES IDO1, INMT, IDO2 POLB 4112/4885NR4A2 4512/4885LMNA 2920/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 POLB 2458/4885NR4A2 2684/4885LMNA 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.